Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Infliximab can prolong remissions, conference told

Infliximab can prolong remissions in some of the most severe cases of Crohn's disease, researchers have reported.

News image

fiogf49gjkf04

A multi-center research team conducted the first large-scale trial of infliximab - also known as 'Remicade' - as maintenance therapy.

After 30 weeks of the study, patients receiving infusions of infliximab every 8 weeks were twice as likely to be in remission as those who were not receiving the drug.

The results of the trial, known as ACCENT-I, were revealed at the Digestive Disease Week meeting in Atlanta, United States.

Infliximab was approved by the Food and Drug Administration 3 years ago for short-term treatment of moderate to severe Crohn's disease and is the only non-steroidal medication indicated for the treatment of fistulas.

The study's director, Dr Stephen Hanauer, a Professor of Medicine at the University of Chicago, said it was the first therapy that truly allowed the disease to be managed over time.

"Ongoing treatment with infliximab decreased disease activity, prevented sudden attacks, and enabled patients to reduce - or, in many cases, completely eliminate - steroids," he commented.

Proportion of patients in remission at Week 30:
Placebo group: 21%
Infliximab, Group II: 39%
Infliximab, Group III: 45%
Digestive Disease Week

Almost 600 patients with moderate to severe Crohn's disease were involved in the study at 55 centers in North America, Europe, and Israel.

All patients received an initial dose of infliximab. The 335 patients (59%) who responded to the initial dose were randomized to one of 3 treatment groups.

All three groups received infusions at Weeks 2, 6, 14, 22, and 30 of the study. Group I received placebo (an infusion containing no medication), Group II received 5 mg/kg of infliximab, and Group III received 5 mg/kg of infliximab at Weeks 2 and 6, followed by 10 mg/kg at Weeks 14, 22, and 30.

By Week 30, patients in Groups II and III were twice as likely to be in remission as patients in Group I who received only the placebo.

Dr Hanauer said that almost 21% of the patients who received placebo had no symptoms at 30 weeks, but nearly 39% of those on the lower dose of infliximab, and 45% of those on the higher dose, were in complete remission.

He said infliximab also helped patients reduce their reliance on steroids; and patients reported higher quality-of-life scores at Week 30 than patients receiving the placebo.

"It would make a real difference for patients if we had alternatives to steroids, or better ways to reduce the steroid dose," said Hanauer.

However, infliximab has also been found to increase the risk of serious infection because it suppresses part of the immune response.

There are also reports of serious infusion reactions with hives, difficulty breathing, and low blood pressure, and in rare cases, people with de-myelinating disease who were treated with infliximab have seen their symptoms intensify.

Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com

Digestive Disease Week
23 May 2001

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us